Pharmaceuticals
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD)....
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
SEOUL, South Korea, April 22, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
SUZHOU, China, April 21, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced thatthe China phase II clinical trial (the "Phase II Clinical Trial") of i...
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards
SINGAPORE, April 18, 2024 /PRNewswire/ -- Juniper Biologics
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards
SINGAPORE, April 22, 2024 /PRNewswire/ -- Juniper Biologics
BGI Genomics Leads Innovation with Inaugural Clinical Lab in Uruguay
Cutting-edge facility to serve as a beacon for preventive medicine in Latin America MONTEVIDEO, Uruguay, April 22, 2024 /PRNewswire/ -- BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory atUruguay's Parque de las Ciencias free trad...
CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US
TAMPA, Fla., April 20, 2024 /PRNewswire/ -- Concept Medical
Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success
* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a mult...
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions
Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a...
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
Siriraj Hospital Shines Spotlight on TAVI Procedure as Alternative for High-Risk Patients Requiring Aortic Valve Replacement
BANGKOK, April 18, 2024 /PRNewswire/ -- Siriraj Hospital, a leading healthcare institution inThailand, stands at the forefront of aortic valve disease treatment with Transcatheter Aortic Valve Implantation (TAVI). The minimally invasive procedure significantly reduces surgical trauma and post-sur...
TaiGen Successfully Completes TG-1000 Phase III Study
TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...
Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"
MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech
incubatorJumar Bioincubator
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is...
Q1 2024 Revenue and Business Update
MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company reports unaudi...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 289 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 288 media titles]
2024-04-22 06:00With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 284 media titles]
2024-04-19 13:25Animated Life in Yunnan
[Picked up by 280 media titles]
2024-04-18 14:00